{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:14:43Z","timestamp":1790957683847,"version":"4.1.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are no direct comparisons of sotatercept to add-on therapies approved for pulmonary arterial hypertension (PAH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to compare the efficacy and safety of add-on sotatercept versus other add-on therapies using a network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and clinicaltrials.gov until April 15, 2023, for randomized trials involving patients with PAH who were treated with add-on sotatercept or other add-on PAH therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Extraction<\/jats:title>\n                    <jats:p>Data extraction and risk-of-bias assessments were performed independently and in duplicate using the Cochrane RoB 2.0 tool. We performed a frequentist random-effects network meta-analysis using the restricted maximum-likelihood estimator and assessed the certainty of evidence using the GRADE (grading of recommendations assessment development, and evaluation) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Synthesis<\/jats:title>\n                    <jats:p>Our search found 18 trials (5,777 patients) eligible for analysis. Sotatercept reduces clinical worsening as compared with placebo (relative risk [RR], 0.21; 95% confidence interval [CI]\u2009=\u20090.11\u20130.41; with high certainty). Sotatercept probably reduces clinical worsening more, compared with add-on endothelin receptor antagonists (RR, 0.28; 95% CI\u2009=\u20090.14\u20130.55), inhaled prostanoid (RR, 40.21; 95% CI\u2009=\u20090.07\u20130.67), and prostanoid taken orally (RR, 0.32; 95% CI\u2009=\u20090.16\u20130.67; all with moderate certainty). Sotatercept probably improves 6-minute-walk distance compared with placebo (mean difference [MD], 36.89\u2009m; 95% CI\u2009=\u200925.26\u201348.51). Although sotatercept probably improves 6-minute-walk distance more than add-on endothelin receptor antagonists (MD, 18.38\u2009m; 95% CI\u2009=\u20095.92\u201330.84) and prostanoid taken orally (MD, 25.66\u2009m; 95% CI\u2009=\u200913.71\u201337.61), it did not exceed the minimal clinically important difference of 33\u2009m (both with moderate certainty).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sotatercept is an effective add-on therapy for PAH, likely superior to many approved add-on PAH therapies in reducing clinical worsening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202311-942oc","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T14:34:17Z","timestamp":1717166057000},"page":"1194-1203","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":12,"title":["Comparative Effectiveness of Sotatercept and Approved Add-On Pulmonary Arterial Hypertension Therapies: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3015-0723","authenticated-orcid":false,"given":"Tyler","family":"Pitre","sequence":"first","affiliation":[{"name":"Division of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairavi","family":"Desai","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Mah","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Zeraatkar","sequence":"additional","affiliation":[{"name":"Department of Health Research, Methods, Evidence, and Impact, and"},{"name":"Department of Anesthesiology, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2892","authenticated-orcid":false,"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, INSERM UMR_S 999, Department of Respiratory and Intensive Care Medicine, Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, ERN-LUNG, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"2026012203162174700_bib1","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"2026012203162174700_bib2","doi-asserted-by":"crossref","first-page":"220036","DOI":"10.1183\/16000617.0036-2022","article-title":"Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis","volume":"31","author":"Pitre","year":"2022","journal-title":"Eur Respir Rev"},{"key":"2026012203162174700_bib3","doi-asserted-by":"crossref","first-page":"2002341","DOI":"10.1183\/13993003.02341-2020","article-title":"Targeting transforming growth factor-\u03b2 receptors in pulmonary hypertension","volume":"57","author":"Guignabert","year":"2021","journal-title":"Eur Respir J"},{"key":"2026012203162174700_bib4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/CIRCULATIONAHA.122.061501","article-title":"Serum and pulmonary expression profiles of the activin signaling system in pulmonary arterial hypertension","volume":"147","author":"Guignabert","year":"2023","journal-title":"Circulation"},{"key":"2026012203162174700_bib5","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-2600(23)00264-3","article-title":"Treatment of pulmonary arterial hypertension: recent progress and a look to the future","volume":"11","author":"Humbert","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026012203162174700_bib6","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012203162174700_bib7","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012203162174700_bib8","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026012203162174700_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026012203162174700_bib10","doi-asserted-by":"crossref","first-page":"107420","DOI":"10.1016\/j.rmed.2023.107420","article-title":"Home high flow nasal cannula for chronic hypercapnic respiratory failure in COPD: a systematic review and meta-analysis","volume":"219","author":"Pitre","year":"2023","journal-title":"Respir Med"},{"key":"2026012203162174700_bib11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.anai.2022.12.018","article-title":"A comparison of the effectiveness of biologic therapies for asthma: a systematic review and network meta-analysis","volume":"130","author":"Pitre","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026012203162174700_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae106","article-title":"Treatments for pulmonary arterial hypertension: navigating through a network of choices","author":"Pitre","year":"2024","journal-title":"Eur Heart J"},{"key":"2026012203162174700_bib13","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026012203162174700_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019","edition":"2nd ed"},{"key":"2026012203162174700_bib15","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"key":"2026012203162174700_bib16","volume-title":"Package \u2018gemtc\u2019: network meta-analysis using Bayesian methods [Version 1.0\u20132]","author":"Van Valkenhoef","year":"2023"},{"key":"2026012203162174700_bib17","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"2026012203162174700_bib18","volume-title":"Package \u2018netmeta\u2019: network meta-analysis using frequentist methods [Version 2.9\u20130]","author":"R\u00fccker","year":"2024"},{"key":"2026012203162174700_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"2026012203162174700_bib20","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"2026012203162174700_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jclinepi.2018.11.025","article-title":"GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence","volume":"108","author":"Brignardello-Petersen","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"2026012203162174700_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","article-title":"GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings","volume":"137","author":"Zeng","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"2026012203162174700_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2023.06.010","article-title":"Grading of recommendations assessment, development, and evaluation concept article 5: addressing intransitivity in a network meta-analysis","volume":"160","author":"Brignardello-Petersen","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"2026012203162174700_bib24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1164\/rccm.201203-0480OC","article-title":"The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension","volume":"186","author":"Mathai","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203162174700_bib25","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012203162174700_bib26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","article-title":"Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial","volume":"9","author":"Hoeper","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026012203162174700_bib27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012203162174700_bib28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203162174700_bib29","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","article-title":"Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension","volume":"30","author":"Barst","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"2026012203162174700_bib30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012203162174700_bib31","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"2026012203162174700_bib32","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"key":"2026012203162174700_bib33","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"key":"2026012203162174700_bib34","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026012203162174700_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12872-017-0674-3","article-title":"Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial","volume":"17","author":"Vizza","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2026012203162174700_bib36","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"28","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"key":"2026012203162174700_bib37","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"key":"2026012203162174700_bib38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/13993003.02044-2014","article-title":"Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension","volume":"46","author":"McLaughlin","year":"2015","journal-title":"Eur Respir J"},{"key":"2026012203162174700_bib39","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203162174700_bib40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S2213-2600(19)30091-8","article-title":"Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial","volume":"7","author":"Sitbon","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026012203162174700_bib41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/hr.2014.28","article-title":"Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension","volume":"37","author":"Zhuang","year":"2014","journal-title":"Hypertens Res"},{"key":"2026012203162174700_bib42","doi-asserted-by":"crossref","first-page":"2201347","DOI":"10.1183\/13993003.01347-2022","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"2026012203162174700_bib43","doi-asserted-by":"crossref","first-page":"2201972","DOI":"10.1183\/13993003.01972-2022","article-title":"Sotatercept for pulmonary arterial hypertension: something old and something new","volume":"61","author":"Rubin","year":"2023","journal-title":"Eur Respir J"},{"key":"2026012203162174700_bib44","doi-asserted-by":"crossref","first-page":"2301513","DOI":"10.1183\/13993003.01513-2023","article-title":"Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle","volume":"62","author":"Price","year":"2023","journal-title":"Eur Respir J"},{"key":"2026012203162174700_bib45","author":"FDA approves Merck\u2019s WINREVAIR (sotatercept-csrk), a first-in-class treatment for adults with pulmonary arterial hypertension (PAH, WHO* Group 1)","year":"2024"},{"key":"2026012203162174700_bib46","author":"Lin","year":"2024"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/8\/1194\/66008390\/annalsats_21_8_1194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/8\/1194\/66008390\/annalsats_21_8_1194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:17:28Z","timestamp":1769069848000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/21\/8\/1194\/8380685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202311-942oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"2023-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}